ES2052602T3 - Nuevos peptidos afines a las linfocinas. - Google Patents

Nuevos peptidos afines a las linfocinas.

Info

Publication number
ES2052602T3
ES2052602T3 ES87810561T ES87810561T ES2052602T3 ES 2052602 T3 ES2052602 T3 ES 2052602T3 ES 87810561 T ES87810561 T ES 87810561T ES 87810561 T ES87810561 T ES 87810561T ES 2052602 T3 ES2052602 T3 ES 2052602T3
Authority
ES
Spain
Prior art keywords
polypeptides
lymphocines
new peptides
mrp
peptides related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87810561T
Other languages
English (en)
Inventor
Karel Gerrit Dr Odink
Roger Dr Clerc
Nico Dr Cerletti
Josef Dr Bruggen
Lajos Dr Tarcsay
Clemens Prof Dr Sorg
Walter Wiesendanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868623850A external-priority patent/GB8623850D0/en
Priority claimed from GB868628358A external-priority patent/GB8628358D0/en
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2052602T3 publication Critical patent/ES2052602T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LA INVENCION SE REFIERE A POLIPEPTIDOS RELACIONADOS CON EL FACTOR DE INHIBICION DE MIGRACION MACROFAGA HUMANA, EN PARTICULAR LOS POLIPEPTIDOS LLAMADOS MRP-8 Y MRP-14, PROCEDIMIENTOS PARA SU PREPARACION, MRNAS, DNAS Y VECTORES HIBRIDOS QUE CODIFICAN PARA DICHOS POLIPEPTIDOS, HUESPEDES TRANSFORMADOS CON TAL VECTOR HIBRIDO, ANTICUERPOS MONOCLONALES Y POLICLONALES PARA DICHOS POLIPEPTIDOS, Y METODOS DE DIAGNOSTICO PARA CONDICIONES INFLAMATORIAS Y FIBROSIS CISTICA.
ES87810561T 1986-10-03 1987-09-28 Nuevos peptidos afines a las linfocinas. Expired - Lifetime ES2052602T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868623850A GB8623850D0 (en) 1986-10-03 1986-10-03 Lymphokine related peptide
GB868628358A GB8628358D0 (en) 1986-11-27 1986-11-27 Lymphokine related peptides

Publications (1)

Publication Number Publication Date
ES2052602T3 true ES2052602T3 (es) 1994-07-16

Family

ID=26291377

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87810561T Expired - Lifetime ES2052602T3 (es) 1986-10-03 1987-09-28 Nuevos peptidos afines a las linfocinas.

Country Status (11)

Country Link
US (2) US5350687A (es)
EP (1) EP0263072B1 (es)
JP (1) JPH09188698A (es)
AU (1) AU7930987A (es)
DE (1) DE3789413T2 (es)
DK (1) DK517787A (es)
ES (1) ES2052602T3 (es)
FI (1) FI874287L (es)
IE (1) IE61773B1 (es)
NO (1) NO874159L (es)
PT (1) PT85849B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2750604B1 (fr) * 1996-07-02 2002-09-20 Oreal Heteromere liant l'acide arachidonique et son utilisation en cosmetique ou pharmacie
EP0463037A1 (en) * 1989-03-17 1992-01-02 Genetics Institute, Inc. Human macrophage migration inhibitory factor
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
JP2747839B2 (ja) * 1989-08-14 1998-05-06 花王株式会社 モノクローナル抗体
US5149544A (en) * 1989-11-13 1992-09-22 Research Corporation Technologies, Inc. Method of inhibiting progenitor cell proliferation
ATE228164T1 (de) * 1990-09-05 2002-12-15 Heart Res Inst Ltd Chemotaktische faktoren
CH685959A5 (de) * 1992-08-24 1995-11-15 Biomedicals Ag Diagnostische Testpackung zur Bestimmung von Proteinen.
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US5776348A (en) * 1995-02-07 1998-07-07 Massachusetts Institute Of Technology Mineral precipitation system and method for inhibiting mineral precipitate formation
JP2001509679A (ja) * 1997-01-21 2001-07-24 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド レセプターをコードするポリヌクレオチドとポリペプチド
WO2000018970A1 (fr) 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Procede de commande de liberation de granules
DE69941627D1 (de) * 1998-11-05 2009-12-17 Univ Michigan Für krebs
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
WO2003069349A2 (en) * 2002-02-15 2003-08-21 Clemens Sorg Method for diagnosis of inflammatory diseases using mrp8/mrp14
AU2003236762A1 (en) 2002-07-05 2004-01-23 Universite Laval Chemotactic factor inhibitor for modulating inflammatory reactions
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7361474B2 (en) * 2003-02-24 2008-04-22 United States Of America As Represented By The Department Of Veterans Affairs Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer
WO2004084928A1 (en) 2003-03-28 2004-10-07 UNIVERSITé LAVAL S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
EP1656376A1 (en) * 2003-08-22 2006-05-17 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US20050196795A1 (en) * 2004-02-25 2005-09-08 Siegler Katherine M. Methods for diagnosing and treating bladder cancer
SE0400886D0 (sv) * 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
WO2006005186A1 (en) * 2004-07-13 2006-01-19 UNIVERSITé LAVAL S100 protein inhibitors for treating leukemia
DE602005025775D1 (de) 2004-07-23 2011-02-17 Aspenbio Pharma Inc Verfahren und vorrichtungen zur diagnose von appendizitis
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
EP1861407A1 (en) * 2005-03-24 2007-12-05 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
EP3075867B1 (en) * 2008-09-03 2019-03-13 Quantumdx Group Limited Sensing strategies and methods for nucleic acid detection using biosensors
WO2012161143A1 (ja) 2011-05-20 2012-11-29 独立行政法人理化学研究所 生物材料用透明化試薬、及びその利用
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
WO2016026956A1 (en) * 2014-08-22 2016-02-25 Baxalta GmbH Detection of cho-mif contaminations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE230876C (es) *
US4322274A (en) * 1980-08-28 1982-03-30 Wilson Gregory B Method of diagnosing cystic fibrosis patients and asymptomatic carrier of the cystic fibrosis gene
GB2125047B (en) 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
GB8318754D0 (en) * 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
JPS6041697A (ja) * 1983-08-15 1985-03-05 Asahi Chem Ind Co Ltd 活性蛋白質誘導体の新規合成法
PH22337A (en) 1983-11-21 1988-08-12 Ciba Geigy Ag Synthesis of fibrinolytic agents by yeast
FI86744C (fi) 1983-11-21 1992-10-12 Ciba Geigy Ag Foerfarande foer framstaellning av eglinfoereningar
JPH0672158B2 (ja) 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines

Also Published As

Publication number Publication date
US5702920A (en) 1997-12-30
EP0263072A2 (en) 1988-04-06
FI874287A7 (fi) 1988-04-04
DK517787D0 (da) 1987-10-02
DE3789413D1 (de) 1994-04-28
AU7930987A (en) 1988-05-19
US5350687A (en) 1994-09-27
PT85849B (pt) 1990-07-31
NO874159L (no) 1988-04-05
IE872645L (en) 1988-04-03
EP0263072B1 (en) 1994-03-23
PT85849A (en) 1987-11-01
EP0263072A3 (en) 1990-01-10
DE3789413T2 (de) 1994-07-28
FI874287L (fi) 1988-04-04
DK517787A (da) 1988-04-04
NO874159D0 (no) 1987-10-02
IE61773B1 (en) 1994-11-30
FI874287A0 (fi) 1987-09-30
JPH09188698A (ja) 1997-07-22

Similar Documents

Publication Publication Date Title
ES2052602T3 (es) Nuevos peptidos afines a las linfocinas.
IT8050355A0 (it) Disposizione di pompe
IT1116876B (it) Procedimento per la sintesi di delta16-pregnani da 17-chetosteroidi
FR2533637B1 (fr) Pompe cryogenique
BE746446A (fr) Route temporaire composee d'elements prefabriques
IT1118005B (it) Strutture composite rinforzate
IT1088128B (it) Apparecchatura per la erezione di scatole
IT1090258B (it) Combinazione perfezioanta di prismi per l'osservazione periscopica
IT7928141A0 (it) Con protezione contro mancanza di ponte raddrizzatore polifase ibrido commutazione.
IT1039744B (it) Procedimento per la preparazione di diepossidi
IT8261999U1 (it) Travetto laterocementizio armato
ATA742579A (de) Verdichter oder verdraenger
IT7950773A0 (it) Valvola di derivazione
CH466187A (de) Ausbau, insbesondere Bogen- oder Ringausbau, für die wasserdichte Auskleidung von unterirdischen Strecken
IT8319708A0 (it) Impianto di gruppi turbo-alternatori.
DK250085A (da) Vektorer til antigenekspression
IT1080471B (it) Metodo per la costruzione di serbatoi
IT1078289B (it) Procedimento per l'isolamento di diamminodifenilmetani
IT8423217A1 (it) Miglioramenti riguardanti la costruzione di pompe ausiliarie per combustibile
IT1059449B (it) Loculo prefabbricato per la costruzione di colombari
IT1237005B (it) Apparecchio di comando della ricerca di bersaglio per siluri
IT8022664A0 (it) Peptidi simili alla somatostatina.
IT7921783V0 (it) Blocco prefabbricato di apparecchi igienico-sanitari.
SU473108A1 (ru) Фазовый способ раздельного уравновешивани моста переменного тока
ATA78882A (de) Schalungsring für schalungen für rundbauten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 263072

Country of ref document: ES